ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy

BACKGROUND: Excision repair cross-complementation group 1 (ERCC1) expression status has been identified as a candidate marker for predicting efficacy of oxaliplatin (OX) treatment for metastatic colorectal cancer (CRC) in several trials. Also, an association between expression of mismatch repair (MM...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, P, Fang, Y J, Li, F, Ou, Q J, Chen, G, Ma, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619275/
https://www.ncbi.nlm.nih.gov/pubmed/23481186
http://dx.doi.org/10.1038/bjc.2013.83

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619275/
https://www.ncbi.nlm.nih.gov/pubmed/23481186
http://dx.doi.org/10.1038/bjc.2013.83

Ejemplares similares